Qualigen therapeutics reports positive qn-247 readout in triple negative breast cancer in vivo model

Carlsbad, calif., aug. 01, 2022 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces it has completed its in vivo efficacy analysis of qn-247 in solid tumors. data demonstrates robust efficacy and no safety signals in a triple negative breast cancer (tnbc) model.
QLGN Ratings Summary
QLGN Quant Ranking